As second-line therapy for PsA and axSpA, no clear treatment-retention benefit at 3 years was seen when swapping to a bDMARD with another MOA.

Ankylosing spondylitis (AS) affects women differently than men. Ankylosing spondylitis symptoms in females may be less associated with the spine.

With new systemic treatments now available for psoriatic disease, questions remain on the comparable efficacy and safety of these therapies.

Panelists discuss the challenges and evolving landscape of step therapy protocols in hidradenitis suppurativa treatment, emphasizing the impact on patient adherence, the potential benefits of earlier ...

The authors comprehensively elaborate on the diversity and complexity of ILs' roles in AKI pathogenesis. The review also describes how ILs coordinate ...